Baird made positive comments and raised their price target on Outperform-rated Optimer Pharmaceuticals (NASDAQ: OPTR) following the company's partnership deal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE